2024-05-02 10:03:17 ET
Summary
- BioAtla is a biotech company focused on developing conditionally activated biologics for cancer therapy.
- Their approach is an attempt to harness the Warburg effect to conditionally activate immunological molecules.
- BioAtla has promising pipeline candidates, including mecbotamab vedotin, ozuriftamab vedotin, and evalstotug, with ongoing clinical studies.
- The BioAtla cash burn rate is high, currently taking the company into early 2025 at best.
Topline Summary
BioAtla ( BCAB ) is a microcap biotech company focused on developing conditionally activated biologics for use in cancer therapy. In this case, rather than using some kind of cleavable mask, BCAB's platform relies on activating antibodies in different microenvironment pH levels, attempting to take advantage of the Warburg effect....
Read the full article on Seeking Alpha
For further details see:
BioAtla: A Buried ADC Concern Gets Some New Life In 2024